July 2020 – Birmingham Angels an Angel Investment Group managed by City Side Ventures just added Pathware LLC to Its portfolio of investments. 


Pathware is bringing hospitals into the age of digital pathology by providing automated systems for biopsy quality assessments. 1 in 5 Biopsy procedures fails to collect a diagnostic sample.  In 2019, US hospitals spent $2B+ repeating 500,000 inadequate biopsy procedures. This unreimbursed care subtracts directly from the hospital’s bottom line.

Pathware is creating software solutions to simplify digital pathology workflows and reduce the rate of repeat procedures. Bioptic™, our cloud-based sample management platform, returns a biopsy quality determination in minutes, verifying that a viable biopsy was collected with greater than 90% certainty.  “Birmingham Angels is pleased to announce our investment and join Tech Coast Angels, The Keiretsu Forum, Level Eight Ventures, and others in closing the round for Pathware. We anticipate a bright future for them.” – David Weaver City Side Venture Chief Investment Officer. Birmingham Angels are committed to supporting early-stage based companies. 

For more information about Birmingham Angels please visit us at: https://citysideventures.com/birmingham-angels/

If you are an accredited investor and would like to schedule a private meeting,

please complete the following request form: https://citysideventures.com/birmingham-angels-individual/

or contact us: dweaver@citysideventures.com; 248.236.7005 Ext. 704

******************